



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Implantation of Intraström Corneal Ring Segments

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 235

BCBSA Reference Number: 9.03.14

NCD/LCD: NA

Related Policies

- Corneal Collagen Cross-linking, #[905](#)
- Keratoprosthesis, #[221](#)
- Endothelial Keratoplasty, #[180](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Implantation of intraström corneal ring segments may be **MEDICALLY NECESSARY** for the treatment of keratoconus in patients 21 years of age or older who meet the following criteria:

- The patient has experienced a progressive deterioration in their vision, such that they can no longer achieve adequate functional vision with contact lenses or spectacles, AND
- Corneal transplantation is the only alternative to improve their functional vision, AND
- The patient has a clear central cornea with a corneal thickness of 450 microns or greater at the proposed incision site.

Implantation of intraström corneal ring segments as a treatment for myopia is **NOT MEDICALLY NECESSARY**.

Implantation of intraström corneal ring segments for all other conditions is **INVESTIGATIONAL**.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO BlueSM	Prior authorization is not required .
Medicare PPO BlueSM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
65785	implantation of intrastromal corneal ring segments

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if medical necessity criteria are met:

ICD-10 Diagnosis Codes

ICD-10 diagnosis codes:	Code Description
H18.601	Keratoconus, unspecified, right eye
H18.602	Keratoconus, unspecified, left eye
H18.603	Keratoconus, unspecified, bilateral
H18.609	Keratoconus, unspecified, unspecified eye
H18.611	Keratoconus, stable, right eye
H18.612	Keratoconus, stable, left eye
H18.613	Keratoconus, stable, bilateral
H18.619	Keratoconus, stable, unspecified eye
H18.621	Keratoconus, unstable, right eye
H18.622	Keratoconus, unstable, left eye
H18.623	Keratoconus, unstable, bilateral
H18.629	Keratoconus, unstable, unspecified eye

Description

Vision Disorders

Keratoconus is a progressive bilateral dystrophy characterized by paracentral steepening and stromal thinning that impairs visual acuity.

Pellucid marginal degeneration is a noninflammatory progressive degenerative disease, typically characterized by bilateral peripheral thinning (ectasia) of the inferior cornea. Deterioration of functional vision results from the irregular astigmatism induced by asymmetric distortion of the cornea, and visual acuity typically cannot be restored by using spherocylindrical lenses.

Treatment

Initial treatment for keratoconus often consists of hard contact lenses. A penetrating keratoplasty (ie, corneal grafting) was traditionally considered the next line of treatment in patients who developed intolerance to contact lenses. While visual acuity is typically improved with penetrating keratoplasty, perioperative complications are an associated risk; long-term topical steroid use is required; and endothelial cell loss occurs over time, which is a particular concern in younger patients. As an alternative, a variety of keratorefractive procedures have been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis (LASIK), although, generally, results of these techniques have been poor. In deep anterior lamellar keratoplasty, pathologic corneal stromal tissue is selectively removed to the level of the Descemet membrane, followed by transplantation of a donor graft. Implantation of intrastromal corneal ring segments (ICRS) represents an additive technique, in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty.

Rigid gas permeable contact lenses may be used to treat pellucid marginal degeneration. ICRS, crescentic lamellar keratoplasty, penetrating keratoplasty, and corneal wedge excision have also been proposed as treatments.

ICRS correct myopia by flattening the center of the cornea and represent an alternative to LASIK and other refractive surgeries. A proposed advantage of ICRS is that their insertion does not affect the central cornea and, thus, their effect is not related to the healing process in the cornea. No corneal tissue is removed, and the implants may be removed or replaced. However, mild myopia is effectively treated with spectacles or contact lenses.

Intrastromal Corneal Ring Segments

ICRS are composed of microthin soft plastic inserts of variable thickness that are placed in the periphery of the cornea. They are inserted through an incision made in the cornea, into which channels have been created by rotating a lamellar dissector or by using a femtosecond laser. One or 2 segments are implanted in each channel, and various implants with a range of thicknesses are available for different degrees of correction. They affect refraction in the eye by physically changing the shape of the cornea (flattening the front of the eye), thereby correcting the irregular corneal shape and restoring a degree of functional vision. If required, the implants can be removed or replaced at a later date.

Summary

Intrastromal corneal ring segments (ICRS) are composed of microthin soft plastic inserts of variable thickness that are placed in the periphery of the cornea. They have been investigated as a means of improving vision in diseases such as keratoconus and pellucid marginal degeneration, and for astigmatism following penetrating keratoplasty.

For individuals who have keratoconus who receive ICRS, the evidence includes primarily single-institution case series. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. A number of single-center case series with sample sizes ranging from 19 to 105 eyes have been published. These series have generally reported that a substantial proportion of patients with keratoconus treated with this device have improved vision at 1 to 2 years of follow-up. More limited data are available on long-term efficacy. ICRS is associated with a number of adverse events and explanation. The net health outcome is uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2009 strongly supported the use of ICRS in a select group of patients with advanced keratoconus whose only other option for restoration of functional vision was the more invasive penetrating keratoplasty. Some clinicians may opt to delay a more invasive procedure, although the success rate of this strategy is as yet unproven. Therefore, use of ICRS may be considered medically necessary in patients with keratoconus who meet the U.S. Food and Drug Administration humanitarian device exemption criteria for use of this device.

For individuals who have pellucid marginal degeneration who receive ICRS, the evidence includes a few case series. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. A small number of case series with fewer than 25 eyes per study have evaluated ICRS in patients with pellucid marginal degeneration. Most reports have assessed devices not available in the United States. In 1 study, which included some patients implanted with Intacs, there was no improvement in uncorrected visual acuity 6 months after surgery. Moreover, explanation occurred in about 20% of eyes due to visual deterioration. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have astigmatism after penetrating keratoplasty who receive ICRS, the evidence includes a few case series. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. Two case series, with 9 and 54 patients, were identified; both used devices not available in the United States. ICRS was associated with adverse events such as extrusion and Descemet membrane detachment. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
4/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
4/2017	New references added from BCBSA National medical policy.
4/2016	New references added from BCBSA National medical policy.
1/2016	Clarified coding information.
11/2015	New references added from BCBSA National medical policy.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
12/2013	New references from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
2/2011	Reviewed - Medical Policy Group - Psychiatry and Ophthalmology. No changes to policy statements.
6/1/2010	BCBSA National medical policy review. Changes to policy statements.
6/2010	New policy, effective 06/2010, describing covered and non-covered indication.
5/2007	BCBSA National medical policy review. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Vega-Estrada A, Alio JL, Brenner LF, et al. Outcomes of intrastromal corneal ring segments for treatment of keratoconus: Five-year follow-up analysis. J Cataract Refract Surg. Aug 2013;39(8):1234-1240. PMID 23747207
2. Alio JL, Shabayek MH, Belda JI, et al. Analysis of results related to good and bad outcomes of Intacs implantation for keratoconus correction. J Cataract Refract Surg. May 2006;32(5):756-761. PMID 16765791
3. Boxer Wachler BS, Christie JP, Chandra NS, et al. Intacs for keratoconus. Ophthalmology. May 2003;110(5):1031-1040. PMID 12750109
4. Colin J. European clinical evaluation: use of Intacs for the treatment of keratoconus. J Cataract Refract Surg. May 2006;32(5):747-755. PMID 16765790

5. Levinger S, Pokroy R. Keratoconus managed with intacs: one-year results. *Arch Ophthalmol.* Oct 2005;123(10):1308-1314. PMID 16219721
6. Siganos CS, Kymionis GD, Kartakis N, et al. Management of keratoconus with Intacs. *Am J Ophthalmol.* Jan 2003;135(1):64-70. PMID 12504699
7. Ziaei M, Barsam A, Shamie N, et al. Reshaping procedures for the surgical management of corneal ectasia. *J Cataract Refract Surg.* Apr 2015;41(4):842-872. PMID 25840308
8. Beniz LA, Queiroz GH, Queiroz CF, et al. Intrastromal corneal ring segments delay corneal grafting in patients with keratoconus. *Arq Bras Oftalmol.* Feb 2016;79(1):30-32. PMID 26840163
9. Heikal MA, Abdelshafy M, Soliman TT, et al. Refractive and visual outcomes after Keraring intrastromal corneal ring segment implantation for keratoconus assisted by femtosecond laser at 6 months follow-up. *Clin Ophthalmol.* Jan 2017;11:81-86. PMID 28096650
10. MirafTAB M, Hashemi H, Hafezi F, et al. Mid-term results of a single intrastromal corneal ring segment for mild to moderate progressive keratoconus. *Cornea.* May 2017;36(5):530-534. PMID 27984365
11. Colin J, Malet FJ. Intacs for the correction of keratoconus: two-year follow-up. *J Cataract Refract Surg.* Jan 2007;33(1):69-74. PMID 17189796
12. Bedi R, Touboul D, Pinsard L, et al. Refractive and topographic stability of Intacs in eyes with progressive keratoconus: five-year follow-up. *J Refract Surg.* Jun 2012;28(6):392-396. PMID 22589292
13. Kymionis GD, Siganos CS, Tsiklis NS, et al. Long-term follow-up of Intacs in keratoconus. *Am J Ophthalmol.* Feb 2007;143(2):236-244. PMID 17184717
14. Fernandez-Vega Cueto L, Lisa C, Poo-Lopez A, et al. Intrastromal corneal ring segment implantation in 409 paracentral keratoconic eyes. *Cornea.* Nov 2016;35(11):1421-1426. PMID 27490048
15. Pinero DP, Alio JL, Morbelli H, et al. Refractive and corneal aberrometric changes after intracorneal ring implantation in corneas with pellucid marginal degeneration. *Ophthalmology.* Sep 2009;116(9):1656-1664. PMID 19643482
16. Kubaloglu A, Sari ES, Cinar Y, et al. A single 210-degree arc length intrastromal corneal ring implantation for the management of pellucid marginal corneal degeneration. *Am J Ophthalmol.* Aug 2010;150(2):185-192 e181. PMID 20570241
17. Arriola-Villalobos P, Diaz-Valle D, Guell JL, et al. Intrastromal corneal ring segment implantation for high astigmatism after penetrating keratoplasty. *J Cataract Refract Surg.* Nov 2009;35(11):1878-1884. PMID 19878819
18. Coscarelli S, Ferrara G, Alfonso JF, et al. Intrastromal corneal ring segment implantation to correct astigmatism after penetrating keratoplasty. *J Cataract Refract Surg.* Jun 2012;38(6):1006-1013. PMID 22624900
19. Ferrer C, Alio JL, Montanes AU, et al. Causes of intrastromal corneal ring segment explantation: clinicopathologic correlation analysis. *J Cataract Refract Surg.* Jun 2010;36(6):970-977. PMID 20494769
20. Kanellopoulos AJ, Pe LH, Perry HD, et al. Modified intracorneal ring segment implantations (INTACS) for the management of moderate to advanced keratoconus: efficacy and complications. *Cornea.* Jan 2006;25(1):29-33. PMID 16331037
21. Samimi S, Leger F, Touboul D, et al. Histopathological findings after intracorneal ring segment implantation in keratoconic human corneas. *J Cataract Refract Surg.* Feb 2007;33(2):247-253. PMID 17276265
22. National Institute for Health and Care Excellence (NICE). Corneal implants for keratoconus [IPG227]. 2007; <https://www.nice.org.uk/guidance/IPG227>. Accessed February 14, 2018.